The critical link between clinical risk stratification and pharmacovigilance in tuberculosis therapy: implications for rifampicin-induced cholestatic jaundice
The critical link between clinical risk stratification and pharmacovigilance in tuberculosis therapy: implications for rifampicin-induced cholestatic jaundice. // Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S2405579426000367?dgcid=rss_sd_all
The critical link between clinical risk stratification and pharmacovigilance in tuberculosis therapy: implications for rifampicin-induced cholestatic jaundice. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. https://www.sciencedirect.com/science/article/pii/S2405579426000367?dgcid=rss_sd_all
“The critical link between clinical risk stratification and pharmacovigilance in tuberculosis therapy: implications for rifampicin-induced cholestatic jaundice.” Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.
@article{article53129,
title = {The critical link between clinical risk stratification and pharmacovigilance in tuberculosis therapy: implications for rifampicin-induced cholestatic jaundice},
journal = {Journal of Clinical Tuberculosis and Other Mycobacterial Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S2405579426000367?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...